Showing all 2 results
-
High grade intraepithelial lesion (HSIL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00 Select options -
ER+/HER2- Metastatic Breast Cancer (mBC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00The ER + / HER2- metastatic breast cancer (mBC) market is relatively large with the highest market share holding CDK4 / 6 drugs, e.g. Pfizer’s Ibrance (palbociclib), Novartis’s Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib). By 2032, these drugs will continue to hold the largest share of the market, but we also expect the market to expand with the addition of new oral SERDs/SARMs/SERMs that will take a combined share of 19.1%, antibody drug conjugates with a share of the 2.9% and AKT inhibitors with a 2.6% share. The sales of the emerging therapies for the treatment of ER+/HER2- mBC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2022-2032 study period, adding a value estimated at a total market of $ 5.6 billion by 2032.
Product Search
Filter by price
Top rated products
Product categories
- Hematology 2
- Market Forecast 16
- Respiratory Diseases 1
- Ophthalmology 1
- Orthopedics 1
- Central Nervous System 7
- Inflammatory 1
- Genetic Disorders 1
- Renal Diseases / Nephrology 6
- Endocrinology 1
- Pipeline Analytics Report 1
- Disease Competitive Landscape Monitoring 1
- Metabolic Disorders 1
- Therapeutic Area 18
- Musculoskeletal Diseases 1
- Oncology 2